{"links":{"html":"https://www.erudio.com/reports/epcore-dlbcl-2-nct05578976","json":"https://www.erudio.com/reports/epcore-dlbcl-2-nct05578976.json","markdown":"https://www.erudio.com/reports/epcore-dlbcl-2-nct05578976.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"epcore-dlbcl-2-05578976"}},"request":"https://www.erudio.com/contact?report=epcore-dlbcl-2-05578976"},"offer":{"cited_commentary_sources":55,"verified_hcp_statements":187,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":29,"optional":true,"price_per_verified_person_usd":15,"price_usd":435,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"epcore-dlbcl-2-nct05578976"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=epcore-dlbcl-2-05578976","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/epcore-dlbcl-2-nct05578976","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T12:13:00.090443Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":46,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":28,"title":"Primary endpoint: Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5"},{"claim_count":36,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":22,"title":"Secondary endpoints"},{"claim_count":25,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":14,"title":"Population and setting"},{"claim_count":12,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":9,"title":"The comparison"},{"claim_count":37,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":25,"title":"Safety and tolerability"},{"claim_count":36,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":16,"title":"Design and conduct"},{"claim_count":53,"coverage":"discussed","id":"A1","source_count":19,"title":"Current treatment choices and comparative positioning"},{"claim_count":36,"coverage":"discussed","id":"A2","source_count":14,"title":"Earlier-line rationale and the EPCORE NHL-2 evidence bridge"},{"claim_count":15,"coverage":"discussed","id":"A3","source_count":6,"title":"Treatment duration, scheduling and response-guided evidence generation"},{"claim_count":15,"coverage":"discussed","id":"A4","source_count":14,"title":"Delivery capacity, affordability, patient support and referral"},{"claim_count":9,"coverage":"discussed","id":"A5","source_count":8,"title":"Downstream cellular therapy, prior-target exposure and later-line research"},{"claim_count":21,"coverage":"discussed","id":"A6","source_count":12,"title":"Regulatory interpretation and geographic applicability"}],"counts":{"cited_sources":55,"claims_by_expression_type":{"comparison":22,"experience":4,"interpretation":45,"opinion":44,"question":9,"restatement":24,"uncertainty":8,"unspecified":31},"claims_by_kind":{"interpretation":4,"source_observation":183},"clinician_statements":70,"evidence_units":99,"findings":12,"organisational_accounts":8,"people_cited":39,"people_identity_verified":29,"people_total":39,"screened_sources":83,"verified_claims":187},"findings_index":[{"id":"F1","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":4,"passages":5,"sources":4,"sources_by_kind":{"commentary":4}},"title":"The central disagreement is what PFS improvement must prove before practice changes"},{"id":"F2","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":6,"restated":2,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":4,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Numerical safety and deaths—not qualitative reassurance—are pivotal to interpretation"},{"id":"F3","structure":{"claims":17,"claims_by_group":{"comparisons":10,"experience":1,"questions":1,"restated":0,"views":5},"has_counterview":true,"limitations":3,"links":{"context":2,"support":18},"ma_question":true,"named_voices":8,"passages":11,"sources":8,"sources_by_kind":{"commentary":8}},"title":"The actual treatment choice remains unresolved: R-CHOP, Pola-R-CHP or epcoritamab plus R-CHOP"},{"id":"F4","structure":{"claims":21,"claims_by_group":{"comparisons":1,"experience":1,"questions":1,"restated":0,"views":18},"has_counterview":true,"limitations":3,"links":{"context":1,"support":24},"ma_question":false,"named_voices":18,"passages":19,"sources":19,"sources_by_kind":{"commentary":19}},"title":"Some reactions are emphatic, but most practice-change language remains prospective"},{"id":"F5","structure":{"claims":20,"claims_by_group":{"comparisons":0,"experience":1,"questions":4,"restated":1,"views":14},"has_counterview":true,"limitations":4,"links":{"context":1,"support":22},"ma_question":true,"named_voices":9,"passages":13,"sources":11,"sources_by_kind":{"commentary":9,"media":2}},"title":"Risk selection is central; benefit should not be assumed uniform across eligible patients"},{"id":"F6","structure":{"claims":24,"claims_by_group":{"comparisons":3,"experience":2,"questions":0,"restated":8,"views":11},"has_counterview":true,"limitations":3,"links":{"context":1,"support":30},"ma_question":false,"named_voices":6,"passages":11,"sources":9,"sources_by_kind":{"commentary":7,"media":2}},"title":"EPCORE NHL-2 supplied the rationale, not a randomized estimate of frontline benefit"},{"id":"F7","structure":{"claims":15,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":8,"views":2},"has_counterview":true,"limitations":3,"links":{"context":1,"support":17},"ma_question":true,"named_voices":5,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Interim timing, independent review and unequal randomization shape confidence in the signal"},{"id":"F8","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":3,"views":5},"has_counterview":true,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":8,"passages":9,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Duration and scheduling raise questions about additional treatment burden and trial design"},{"id":"F9","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":2,"questions":3,"restated":1,"views":9},"has_counterview":true,"limitations":3,"links":{"context":2,"support":15},"ma_question":true,"named_voices":13,"passages":16,"sources":14,"sources_by_kind":{"commentary":12,"media":2}},"title":"Access, capacity and cost could determine whether a promising regimen is deliverable"},{"id":"F10","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":5},"has_counterview":false,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":5,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Molecular response is proposed as a route to selective escalation—and eventually less treatment"},{"id":"F11","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":7},"has_counterview":true,"limitations":5,"links":{"context":2,"support":9},"ma_question":true,"named_voices":6,"passages":8,"sources":8,"sources_by_kind":{"commentary":8}},"title":"Open sequencing questions coexist with predictions of a sharp decline in cellular therapy"},{"id":"F12","structure":{"claims":24,"claims_by_group":{"comparisons":4,"experience":0,"questions":2,"restated":8,"views":10},"has_counterview":true,"limitations":4,"links":{"context":2,"support":28},"ma_question":true,"named_voices":10,"passages":13,"sources":12,"sources_by_kind":{"commentary":12}},"title":"Regulatory fit and the competing evidence base remain conditional"}],"medical_affairs_question":"What absolute benefit, survival, safety, subgroup and delivery evidence would justify adding treatment rather than continuing an established frontline option?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. PFS, cure and the threshold for changing practice"},{"id":"section-2","level":2,"title":"2. Safety needs numbers, causes of death and patient experience"},{"id":"section-3","level":2,"title":"3. A positive R-CHOP comparison does not settle the real prescribing choice"},{"id":"section-4","level":2,"title":"4. Strong enthusiasm is not the same as an established treatment transition"},{"id":"section-5","level":2,"title":"5. Selection should separate unmet need from assumed uniform benefit"},{"id":"section-6","level":2,"title":"6. EPCORE NHL-2 explains anticipation, with important evidence boundaries"},{"id":"section-7","level":2,"title":"7. Methods criticism is conditional, not a dismissal of the result"},{"id":"section-8","level":2,"title":"8. Extra exposure, antibody pairing and scheduling warrant their own questions"},{"id":"section-9","level":2,"title":"9. Capacity and affordability may constrain action even with favorable data"},{"id":"section-10","level":2,"title":"10. MRD-driven escalation and de-escalation remain hypotheses"},{"id":"section-11","level":2,"title":"11. CAR-T consequences are predictions, not demonstrated displacement"},{"id":"section-12","level":2,"title":"12. Approval and competitive positioning are separate from a positive trial"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":9},{"id":"F5","shared_claims":2},{"id":"F7","shared_claims":11},{"id":"F12","shared_claims":4}],"id":"T1","label":"Primary endpoint: Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":10},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":6},{"id":"F6","shared_claims":6},{"id":"F7","shared_claims":3},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":5},{"id":"F10","shared_claims":7},{"id":"F11","shared_claims":2},{"id":"F12","shared_claims":5}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":19},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":2},{"id":"F9","shared_claims":3},{"id":"F10","shared_claims":1},{"id":"F11","shared_claims":2},{"id":"F12","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":3},{"id":"F8","shared_claims":4},{"id":"F9","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":14},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":5},{"id":"F6","shared_claims":7},{"id":"F7","shared_claims":4},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":8},{"id":"F10","shared_claims":3},{"id":"F11","shared_claims":1},{"id":"F12","shared_claims":6}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":3},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":8},{"id":"F7","shared_claims":14},{"id":"F8","shared_claims":8},{"id":"F9","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T12:13:00.090443Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T12:24:14Z","record_hash":"ba71fdc48f6cafd74bd384ffbd72df2123b4c796d726e83d338bf9d3983c832a","release_hash":"319cb6fe50ae8c9b8fef961112c6e66b51750a2743546e3d549e472a52287feb","report_id":"erudio-nct05578976","run_id":"67fba126-dc22-4d16-964e-98644a402afd","schema_version":"5.0","slug":"epcore-dlbcl-2-05578976","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on EPCORE DLBCL-2 in the sources reviewed for this edition leads to one open question: What absolute benefit, survival, safety, subgroup and delivery evidence would justify adding treatment rather than continuing an established frontline option? Its leading findings: (1) the central disagreement is what PFS improvement must prove before practice changes. (2) numerical safety and deaths—not qualitative reassurance—are pivotal to interpretation. (3) the actual treatment choice remains unresolved: R-CHOP, Pola-R-CHP or epcoritamab plus R-CHOP. 9 more findings follow. 83 sources screened, 55 cited; not all HCPs or all public discussion.","meta_description":"83 sources screened · 187 verified statements (70 from clinicians verified by NPI or staff page) from 55 sources · 12 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-31T12:24:14Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":83},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on alternative bispecific-antibody chemotherapy strategies for previously untreated intermediate- or high-risk diffuse large B-cell lymphoma.","Not yet captured in this edition: a view on biology-guided selection of targeted additions to frontline treatment in newly diagnosed diffuse large B-cell lymphoma.","Not yet captured in this edition: a view on frontline CAR-T as an alternative to chemoimmunotherapy escalation in very-high-risk newly diagnosed lymphoma.","Not yet captured in this edition: a view on targeted additions to frontline chemotherapy for high-risk newly diagnosed diffuse large B-cell lymphoma.","Not yet captured in this edition: a view on frontline epcoritamab plus R-CHOP efficacy, safety and the need for randomized evidence.","Not yet captured in this edition: a view on frontline bispecific escalation using an alternative chemoimmunotherapy backbone in newly diagnosed diffuse large B-cell lymphoma.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","75 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion. Some relevant passages were not fully assessed, and unnamed or differently worded references may be missing.","Source totals do not measure independent HCP support: the material includes repeated posts, quoted announcements, organizational accounts and reactions to the same information.","No original results publication or full protocol for EPCORE DLBCL-2 was available. Phase III result descriptions are largely sponsor topline information relayed through commentary, and some methods are secondary descriptions.","At the time of the cited topline discussions, absolute PFS by arm, OS, detailed response and safety outcomes, follow-up, event counts and geographic enrollment were not fully reported. Their absence cannot establish no benefit, no harm or lack of applicability.","Earlier EPCORE NHL-2 findings concern a small high-risk cohort, different treatment exposure and different reporting time points. They cannot be pooled with, or substituted for, randomized EPCORE DLBCL-2 outcomes.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","This edition does not fully capture the February 2026 reasons for selecting or withholding alternative frontline regimens, or every conditional question about subsequent cellular therapy. It should not be used as a complete account of those exchanges.","Predictions about standard of care, cure, CAR-T displacement, later-line research funding, regulatory pathways and timing remain predictions. References to other settings are used only where the speaker explicitly applies them to interpreting this frontline decision.","Post and publication dates are not necessarily session dates. Pre-result expectations, earlier-study interviews and topline reactions do not establish changes of mind. Speculation about ASH does not confirm a scheduled full-data presentation."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":6,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":43,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":55},"count":55,"evidence_window":{"end":"2026-10-29","start":"2023-06-15"},"retrieval_snapshot":"2026-10-31T11:05:04.704768Z","timeline":[{"count":1,"week":"2023-W24"},{"count":2,"week":"2024-W46"},{"count":1,"week":"2024-W47"},{"count":1,"week":"2024-W49"},{"count":2,"week":"2024-W50"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W06"},{"count":2,"week":"2026-W13"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W26"},{"count":2,"week":"2026-W37"},{"count":35,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W44"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05578976:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05578976:context","quote_policy":"short_quote_link_out"},{"id":"openfda:d7836711-b677-412d-bf2d-0f7c8444103a:20260622","quote_policy":"short_quote_link_out"},{"id":"openfda:c961a1ac-6705-4756-9abc-9d84a6fcb5c8:20260903","quote_policy":"short_quote_link_out"},{"id":"openfda:9af3ddc7-4217-417a-ac89-8704edc5bc44:20260713","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4w7jzkpdswrg7tf4azxu3gsc-3mxb4aihs3d2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7sx4xfvdi6ayikr76lbjpn4p-3mxavjjgkqk2k","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mx5rn3t2us27","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mg4pvv3xwuiuqsco52mmnxrz-3mybvxltghi2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-plgt5bqnko7dwhzi2436ipuf-3law2drcb4d24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-plgt5bqnko7dwhzi2436ipuf-3lb7bojucrk2v","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7512972665347878912","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7513223758929657857","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7513230671591632896","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7513334358951219200","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7513344919361441792","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7514803553413111809","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:74fc80","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8bc9d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1669364763992760321:840be970-364f-43d9-bf60-f13c422b780a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1676693689450524673:ad53c58e-3076-4138-aef9-0ba9680dea41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1857064700053221542:da92137b-f7b9-480a-96dc-41c900ec8d06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1865866318966350143:76d207fe-63c0-4f9b-83ab-be5802cc0342","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866176080308293916:f18d14c5-abf9-484f-ad14-e08931205c6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866176119474704493:966dd126-1d03-47a6-8004-ab3d8db8167e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1877444408108351734:0344e8c8-bcaf-4a86-bfd2-c03d9a70ef1f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981592578077188097:9ec96fa6-34fb-48da-b560-148f136d380e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013574730918527445:65fd8e9b-3366-452d-beef-6c8ddb5a8e64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2019754370779185432:71192851-40a2-4e30-96b1-78abbbc967f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037090804385398901:5becd3a4-1050-453b-b3f5-7ebc62930a92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037463949403095457:6e44b327-6cfb-4123-96e7-d02cb102fbc7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065710389824835701:15f22562-6b87-4912-b057-313dd66967b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098500182945976503:6241acbf-dc4c-490b-9e38-e2ff33ad7e0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098810703926772221:12f90171-08e8-4d9d-8902-10ed3cf62ec2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098811285844394298:20768fca-827f-4e0c-97cf-8c00d74bac01","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098811447409013133:3027684c-01bc-445e-aa94-b690eab4af71","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107167434398462200:c1e9322c-07eb-4b38-a01f-3d4b7452cb80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107182680748212499:caf68af4-fa85-4a32-8608-ce20ce0ee2f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107183227643253036:5528f200-351e-4094-ad77-f390a47f10df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107192197934088451:70e70a2c-b6c0-49b0-9898-903bd11a80c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107199766752858355:477af169-d7ae-4475-b2ce-5bf76e9f81e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107202316428353614:a4b60da2-38f3-4a4d-8501-eaddf5e5ca17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107209378176671832:a5e5c554-98d4-4309-8b24-64d89ecd95d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107209688194629691:560cefa5-3395-4b87-9b1c-1c40af0fcf25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107213918305148985:d7124241-3c90-434d-9bcc-4aac13be306e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107219016712613900:a2f70ed4-90b9-4cc6-ab00-ba70cbcf5c55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107223069437685796:707f1979-83b8-44d6-b942-2db0ae027bd4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107226793476583664:296ff2ae-5765-4bdd-85cd-4618c914fa7a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107232366099927490:a2c81ac6-7f73-4fb3-afd9-18a55caf4e3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107234915242979351:5b35e5f0-860f-446c-8604-2036a907b4c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107242598431674462:305b53a9-b134-4e39-81c0-95b4a25e1733","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107249414674981130:32964012-981b-439e-8de0-f2153a8450c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107273888098816383:82ee488a-dafa-4380-a2a8-8a7fb69225de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107298415302643771:9355ce6a-c6eb-45ad-9d04-cdddcb766010","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107326292639027246:1f0e9a71-5d43-49c9-9622-d6356d81d761","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107345799189610678:fb19c190-c944-4c4d-82f6-2629ec535750","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107374145713676464:6f55c1aa-2d7c-4854-9336-8b5817308dbd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107411845137219939:92c6bd8c-5381-41a8-b2de-29204aab24c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107424051010670917:a3b97d23-be18-454e-9c1e-7f7bd8fe0dfc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107468653859836228:f9baa64f-aa72-4acb-ac3a-1042fd271227","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107475989030978029:abad1451-4b24-4054-be7b-08473fae3255","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107493123752599679:7d7227d7-1914-4d19-bbdf-381495e19084","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107494095094702242:f39fc1c1-78ed-4eb1-ac02-10f962b6ef6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107502590762287195:3adc5f47-0540-4ae7-91e7-ee2c23ab039a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107503693281271923:ea5cb443-04ec-43f7-be59-a5ba04c0e64e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107515095404450113:5c5dfa6e-f167-48b7-9381-eda34cf741a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107522301973725543:87bddd07-2dd6-464f-9ed2-c46d36bcd13d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107561938549088755:adb3670e-ac38-4a25-9198-7e836e075523","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107562327566352560:b947e5d6-6e4d-45a6-bab0-20ff21facac1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107674285233918190:4e564d86-baae-485f-912b-06d11cb0d444","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107727631454245093:7bbbffe6-a7d5-4114-a6df-3fd74d5553e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107757825619378510:eaef988a-5a56-483b-b5bf-f1b232ce33de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107761980152930652:0f96bfaa-2c2c-466c-a863-fd658ab8c84e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107818222569566623:f32958c8-532e-40c0-b693-733cb34f2de0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107863834090184912:509e14bd-e525-448b-88d1-ffd22db0ddb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107904871156621777:7b432035-fd59-433a-af14-ef10b7878945","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107967041097683203:108841e9-9dde-4bd2-861a-9dd9e401afc8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108225476611178981:4285b483-6086-4be0-b8fa-ebcc059e1cb8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108313153457267075:6ba1beff-5e9a-450d-b2c7-949ed93368c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108631311577461141:cc7d5c48-9a14-4be6-afa2-faf0559d3082","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108670188287844826:366d4734-595a-40c5-a593-3ec7932f7613","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109154863594738021:2a1b3aa4-ea64-4d7c-b2e8-37a0e5b40a3c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109244278027526321:808dd3bc-09d1-44b7-8df6-e8c6025e2397","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111135689190379933:0bb6e811-2db7-4fc5-81c3-a7fe30eabcad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111444115393028580:1082367b-4ea7-48df-a410-5951e7a392d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115874570284748814:9a61f559-0ece-4073-a1da-6451ee3613de","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:1BsYphv1sLQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4Sk2CD66a38","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":6,"linkedin_post":6,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":67,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":83},"count":83,"evidence_window":{"end":"2026-10-29","start":"2023-06-15"},"retrieval_snapshot":"2026-10-31T11:05:04.704768Z","timeline":[{"count":1,"week":"2023-W24"},{"count":1,"week":"2023-W27"},{"count":2,"week":"2024-W46"},{"count":1,"week":"2024-W47"},{"count":1,"week":"2024-W49"},{"count":2,"week":"2024-W50"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W06"},{"count":2,"week":"2026-W13"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W26"},{"count":4,"week":"2026-W37"},{"count":57,"week":"2026-W41"},{"count":2,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: epcoritamab","status":"unmapped"},{"brand_names":["Cytoxan","Frindovyx","Neosar"],"label":"cyclophosphamide","slug":"cyclophosphamide"},{"brand_names":["Rituxan"],"label":"rituximab","slug":"rituximab"},{"brand_names":["Oncovin","Vincasar","Vincrex"],"label":"vincristine","slug":"vincristine"},{"brand_names":["Adriamycin","Rubex"],"label":"doxorubicin","slug":"doxorubicin"},{"brand_names":["Cortan","Delta-Dome","Deltasone","Fernisone","Liquid Pred","Meticorten","Orasone","Paracort","Prednicen-M","Rayos","Servisone"],"label":"prednisone","slug":"prednisone"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Diffuse large B-cell lymphoma","slug":"diffuse-large-b-cell-lymphoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"EPCORE DLBCL-2","aliases":["EPCORE DLBCL-2","A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)"],"brief_title":"A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Diffuse Large B-Cell Lymphoma"],"display_condition":"newly diagnosed diffuse large B-cell lymphoma","display_interventions":[["epcoritamab"]],"enrollment":{"count":900,"type":"ESTIMATED"},"interventions":[{"name":"Epcoritamab","synonyms":["ABBV-GMAB-3013"],"type":"DRUG"},{"name":"Cyclophosphamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Rituximab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Vincristine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Doxorubicin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Prednisone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05578976","official_title":"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the duration from randomization to the date of disease progression as determined by Lugano 2014 criteria as assessed by Independent Review Committee (IRC), or death due to any cause whichever comes first.","measure":"Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5","timeFrame":"Up to Approximately 46 Months"}],"registered_date":{"date":"2022-10-13","type":"ACTUAL"},"registry_last_updated":"2026-09-11","registry_url":"https://clinicaltrials.gov/study/NCT05578976","short_name":"EPCORE DLBCL-2","short_name_basis":"registry_acronym","sponsor":"Genmab","start_date":{"date":"2023-02-08","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"M20-621","type":"sponsor_study_id"},{"domain":"EU CT","id":"2023-505277-32","type":"other"}],"study_type":"INTERVENTIONAL"}}}